OXFORD JOURNAL
OF STUDENT
SCHOLARSHIP

Antibiotic Resistance: Mechanisms of Drug Failure and Role of Molecular Docking in Antibiotic Development

İrem Ünlü
iremunlu.app@gmail.com

ABSTRACT

The rapid rise of antimicrobial resistance (AMR) is a serious global health crisis that compromises the effectiveness of conventional antibiotic treatments. This paper describes the main biochemical targets of antibiotics, such as peptidoglycan assembly, ribosomal protein synthesis, and nucleic acid replication, and the evolutionary strategies of bacterial resistance. The main mechanisms of bacterial resistance are enzymatic inactivation, target modification, active efflux systems and decreased outer-membrane permeability. However, traditional drug discovery is often not able to keep pace with evolving pathogens, and computational biology has become an integral part of modern therapeutic research. In particular, this review is focused on molecular docking as a structure-based approach to pre-screen chemical libraries, predict binding orientations and evaluate protein-ligand interactions. As an example of the computational procedure, a docking study of ciprofloxacin with Escherichia coli DNA gyrase B was carried out with SwissDock and visualized with PyMOL. The simulation demonstrated encouraging binding scores and specific interaction distances within the target's binding pocket. The integration of computational tools with a thorough understanding of the bacterial resistance mechanisms will ultimately be the key to an acceleration of the discovery and development of new and robust antibacterial agents.

1: INTRODUCTION

The discovery of antibiotics stands as one of the most important scientific discoveries of the 20th century, and it profoundly transformed modern biomedicine and defined its current boundaries. While the term “antibiotics” is relatively modern, the practice of using antimicrobial agents to fight infections dates back to ancient civilizations. These early societies often relied on various natural extracts from plants and molds for their therapeutic properties [1]. Some of these natural substances demonstrated clear antibacterial effects long before the formal concept of antibiotics was ever established [2]. The term itself was later introduced by the American microbiologist Selman Waksman and his team, who succeeded in isolating specific chemical substances from microorganisms that could inhibit the growth of others [3]. Even though these ancient roots are well-documented, the era of modern antibiotic therapy officially began in 1928 with Alexander Fleming’s accidental discovery of penicillin [4] [5].

A fundamental aspect of antimicrobial agents is their ability to target specific sites that are vital for the growth and survival of microbes. By interfering with these functions, the agents either become lethal to the cells or effectively inhibit their growth [6]. The target must either be completely absent from mammalian cells or it must be different enough from its human equivalent in order to allow for an effective and safe antimicrobial action. [7]. The peptidoglycan layer of the bacterial cell wall is a perfect example of such a target, as it is essential for the survival of most bacteria but possesses a chemical structure unlike any human macromolecule [8]. Consequently, the enzymes responsible for the synthesis of this layer are ideal targets for selective drugs. Most other classes of antibiotics also act on targets that exist in human cells but differ significantly enough to ensure safety [9].

However, the rise of Antimicrobial Resistance (AMR) has become a critical global concern in the 21st century. AMR occurs when microorganisms like bacteria and viruses evolve to the point where standard medications can no longer treat the infections they cause [10]. The rapid spread of resistant strains and a lack of new drugs entering the market caused a drastic incline in this crisis. [11]. One of the primary drivers of this issue is the irresponsible or excessive use of antibiotics in clinical settings, agriculture, and animal healthcare [12]. Often described as a "Silent Pandemic," AMR is an urgent challenge that requires immediate management rather than being viewed as a distant problem [13]. Without effective intervention, it is estimated that AMR could become the leading cause of death worldwide by 2050, with annual fatalities potentially reaching 10 million [14] [15].

Given these significant risks, there is an urgent need for more efficient methods in the discovery of new antibacterial agents. Traditional screening processes are frequently slow, expensive, and struggle to keep up with evolving pathogens [16]. This is why computational approaches have become essential in modern research. Technological advancements have made it much easier to understand the biology and epidemiology of diseases [17]. Specifically, the field of computational biology has evolved rapidly over the last decade, providing deep insights into how diseases spread, how virulence factors function, and how resistance mechanisms develop, ultimately supporting the creation of novel therapeutic agents [18] [19].

To provide a structured overview of the subject, the literature reviewed in this paper was identified through systematic searches of PubMed, Scopus, and Google Scholar using keywords including "antibiotic resistance," "molecular docking," "DNA gyrase," and "antibacterial drug discovery." Peer-reviewed primary research articles, review papers, and international clinical reports were considered, with priority given to sources directly addressing mechanisms of antibiotic action, bacterial resistance, and computational approaches to antibacterial drug development. This paper examines the primary mechanisms of antibiotic action, the strategies bacteria use to resist them, and the growing role of computational methods in the development of new treatments.

2: ANTIBIOTIC TARGETS AND MECHANISMS OF ACTION

Antibiotics work because they utilize major structural and biochemical differences between bacterial cells and human cells. The most important antibacterial targets are peptidoglycan assembly, the 70S ribosome,

bacterial DNA topoisomerases, bacterial RNA polymerase, the Gram-negative outer and inner membranes, and the de novo folate pathway. These mechanisms also predict the spectrum of activity, bactericidal versus bacteriostatic behavior, toxicity, and the most likely routes by which resistance will emerge. [21–23,26,27,31,32,35–37,39–41,43,44].

Antibiotics target essential bacterial structures or processes that are crucial for survival and replication to exert their effects. These targets are chosen because of their significant differences from those in human cells, which allows for high therapeutic specificity. The primary mechanisms of action include inhibition of cell wall synthesis, disruption of protein synthesis, interference with nucleic acid synthesis, damage to cell membrane integrity, and inhibition of key metabolic pathways. Understanding these mechanisms is fundamental to explaining both antibiotic efficacy and the emergence of resistance. [21,22,26,31,35,39,43,44].

One of the most important antibiotic targets is the bacterial cell wall, especially the peptidoglycan sacculus that protects the cell from osmotic rupture and helps determine morphology. Peptidoglycan consists of alternating N-acetylglucosamine and N-acetylmuramic acid residues linked to short stem peptides that are cross-linked to generate a mechanically resilient mesh. Gram-positive bacteria generally have a thick peptidoglycan layer, whereas Gram-negative bacteria contain a thinner peptidoglycan layer in the periplasm beneath an outer membrane rich in lipopolysaccharide and porins. These architectural differences strongly impact drug penetration and spectrum [21,22]. The terminal D-Ala-D-Ala motif of the peptidoglycan precursor is essential to wall assembly because it is recognized during transpeptidation by penicillin-binding proteins (PBPs), which are the enzymes that catalyze final cross-link formation. β-lactam antibiotics act as structural mimics of the acyl-D-Ala-D-Ala substrate and covalently acylate the active-site serine of PBPs, thus blocking transpeptidation, weakening the wall, and predisposing the bacterium to lysis during active growth [20,21]. Because peptidoglycan synthesis is normally regulated with controlled wall cleavage, inhibition of PBPs can result in dysregulation of autolysins and related hydrolases, creating a mismatch between wall construction and wall degradation. Classic work in Escherichia coli linked β-lactam exposure to triggered autolytic degradation, and later mechanistic studies showed that β-lactams can drive a futile cycle of attempted synthesis and lytic cleavage that amplifies lethality [23–25]. These structural facts explain why many cell-wall agents work best against actively dividing bacteria and why Gram-negative organisms are often essentially harder to treat. The outer membrane imposes an additional permeability barrier, while periplasmic enzymes and altered porin profiles can reduce effective drug access to PBPs [21–23].

Another major antibiotic target is the bacterial ribosome. Bacteria use a 70S ribosome composed of 30S and 50S subunits, whereas human cytosolic ribosomes are 80S. This structural difference provides the basis for selective inhibition of bacterial translation [26,27]. Tetracyclines bind the 30S subunit near the A-site region of 16S rRNA and prevent aminoacyl-tRNA accommodation, therefore interrupting elongation. This mechanism does not destroy the ribosome outright, but it arrests the addition of new amino acids and suppresses protein output needed for growth and adaptation [26–28]. Aminoglycosides also target the 30S subunit, but they act differently. By binding the decoding center of 16S rRNA, they promote misreading of mRNA, and can disrupt initiation, resulting in the production of aberrant proteins.

Mistranslation produces dysfunctional proteins that can escalate envelope stress and irreversible cellular injury [26,27,30].In contrast, macrolides bind to 23S rRNA within the 50S subunit at the entrance of the nascent peptide exit tunnel. This placement allows them to obstruct peptide elongation and cause context-dependent translational arrest. The exact outcome depends on the drug and on the nascent peptide sequence, but the overall result is reduced protein production and impaired bacterial growth [26,27,29].

Certain antibiotics interfere directly with bacterial information processing. Fluoroquinolones target the bacterial type II topoisomerases DNA gyrase and topoisomerase IV, which are the enzymes required for supercoil correction, replication fork movement, and chromosome segregation. Quinolones stabilize cleavage complexes between enzyme and DNA, and they convert essential topoisomerases into lesions that damage chromosomes, which can lead to cell death [31,32]. Although both enzymes can be targets, the dominant primary target often differs by organism, with DNA gyrase frequently more important in many Gram-negative bacteria and topoisomerase IV relatively more important in several Gram-positive species. This distinction matters because the order in which target mutations arise can affect both the level and trajectory of fluoroquinolone resistance [31,32]. Rifamycins act on transcription rather than replication. Rifampicin binds the β subunit of bacterial RNA polymerase and sterically blocks the path of the nascent RNA transcript, preventing effective extension after only a few nucleotides have been added. In consequence, transcription initiation fails, gene expression collapses, and downstream protein synthesis is secondarily suppressed [33,34].

Some antibiotics kill bacteria by targeting membrane integrity itself. Polymyxins are cationic lipopeptides that are especially active against Gram-negative bacteria because they bind lipid A within lipopolysaccharide in the outer membrane. By displacing stabilizing divalent cations such as Mg^{2+} and Ca^{2+}, they destabilize membrane packing and damage both the outer and inner membranes, leading to leakage of cellular contents and cell death [35,36]. Because membrane-active compounds can interact with mammalian membranes and are handled by renal tubular cells in ways that favor intracellular accumulation, polymyxins are associated with clinically important nephrotoxicity and, less commonly, neurotoxicity. For that reason, they are generally reserved for situations in which safer alternatives are unavailable or ineffective [37–38].

Antibiotics can also use metabolic differences between bacteria and humans. A classic example is folate biosynthesis in which bacteria must synthesize tetrahydrofolate de novo, whereas humans largely rely on dietary folate. This difference creates selective toxicity and makes the folate pathway an enduring antibacterial target [39,40]. Sulfonamides act as structural analogues of para-aminobenzoic acid and inhibit dihydropteroate synthase, while trimethoprim inhibits dihydrofolate reductase. Inhibition of these two enzymatic steps

reduces tetrahydrofolate production, thereby limiting one-carbon transfer reactions required for thymidylate, purine, and some amino acid biosynthesis. For this reason, the trimethoprim-sulfonamide combination can produce synergistic antibacterial effects that are stronger than either agent alone [41,42]. Structural studies of dihydropteroate synthase have clarified how sulfonamides occupy the enzyme's substrate-binding region and how resistance-associated substitutions can reduce drug affinity while

preserving catalytic competence. This is one reason folate-pathway inhibitors remain useful but are especially vulnerable to target modification, target replacement, and pathway bypass [40,41].

3: RESISTANCE MECHANISMS AGAINST ANTIBIOTIC TARGETS

One of the classical mechanisms of resistance is the chemical inactivation of the antibiotic by bacterial enzymes. The best-known example is the β-lactamases. These enzymes hydrolyze the β-lactam ring and thus inactivate cell wall-active agents such as penicillin, cephalosporins, monobactams, and carbapenems. For this reason, β-lactamase production is regarded as one of the most important determinants of β-lactam failure, especially in Gram-negative bacteria [45]. Extended-spectrum β-lactamases can hydrolyze newer cephalosporins, while plasmid-mediated AmpC enzymes can confer resistance against both broad-spectrum β-lactams and traditional β-lactamase inhibitor combinations [45,46].

The significance of enzymatic inactivation results from its ability to destroy the drug and from the rapid diversification of these enzymes under selective pressure. The β-lactamase repertoire allows new variants to emerge in clinical settings in a relatively short time. As a result, even when the biological target remains present, treatment may fail because the antibiotic is eliminated before it can act in its active form [45]. The same logic applies to other enzyme-mediated resistance phenomena, including aminoglycoside-modifying enzymes. In this mechanism, resistant bacteria can neutralize the drug before it reaches that target rather than changing the target. [43,44].

A second major strategy is the alteration of the antibiotic target or its binding site. In this case, structural changes in the binding region weaken the interaction while the drug remains present in the environment. Target modification may arise through point mutations, ribosomal RNA methylation, acquisition of alternative target proteins, or selection of low-affinity variants of the target enzyme [43,44]. This mechanism is clinically important particularly for essential targets such as the ribosome, DNA gyrase/topoisomerase IV, and RNA polymerase [26,27,31,32].

For antibiotics that inhibit protein synthesis, structural changes in ribosomal binding pockets can reduce the activity of macrolides, aminoglycosides, and other ribosome-active agents. Similarly, in fluoroquinolone resistance, mutations in DNA gyrase or topoisomerase IV reduce the ability of the drug to stabilize the enzyme–DNA complex [26,27,31,32]. In cell wall targeting agents, alternative or low-affinity penicillin-binding proteins may allow peptidoglycan synthesis to continue despite the presence of β-lactams [43,44]. Therefore, target modification does not eliminate the pharmacological presence of the drug, but it suppresses its biological effectiveness.

Active efflux systems may be viewed as a cellular analogue of drug clearance in antibiotic resistance. These transporters reduce the intracellular free antibiotic concentration by pumping the drug out of the cell. In Gram-negative bacteria, resistance–nodulation–division systems form tripartite complexes linking the inner membrane, a periplasmic adaptor, and an outer-membrane channel. This enables direct removal of antibiotics into the external environment. [47,48].

The clinical importance of efflux has two aspects. First, it may directly confer low-to-moderate resistance and raise the minimum inhibitory concentration above the therapeutic threshold. Second, it may buy time for the bacterium to accumulate additional resistance events such as target mutations or enzymatic inactivation [47]. Because many pumps display multidrug substrate profiles, they may affect tetracyclines, fluoroquinolones, chloramphenicol, and some β-lactams simultaneously, thus they broaden the resistance phenotype across several antibiotic classes [47,48].

In Gram-negative bacteria, the outer membrane is one of the principal physical barriers limiting antibiotic access to the target. Many hydrophilic agents enter the periplasm through porin channels; consequently, reduced porin expression, altered channel diameter, or changes in selectivity directly restrict drug influx. Thus, even when the target remains intact and the antibiotic itself is chemically stable, an effective intracellular concentration may fail to develop [49,50].

Reduced permeability is most important when it acts in concert with other resistance mechanisms. For example, loss of outer-membrane porins can considerably enhance the effect of AmpC enzymes or carbapenems, because less drug enters the cell while the fraction that does enter is more readily eliminated in the periplasm [46,49]. Similarly, the combination of low permeability with active efflux restricts antibiotic flux in both directions (entry is decreased and exit is increased). [47,49,50].

4: COMPUTATIONAL APPROACH IN ANTIBIOTIC DISCOVERY

4.1 Molecular Docking:

Molecular docking is a structure-based computational method that predicts the binding orientation and positions a small molecule may adopt within the binding pocket of a target protein. In antibacterial drug discovery, this approach allows large chemical libraries to be pre-screened before laboratory testing, so that experimental resources can be concentrated on higher-probability candidates [51–53]. When high-resolution target structures are available, docking enables rapid and systematic comparison of large numbers of compounds against the same biological target [51,53].

One of the principal strengths of docking is that it supports qualitative interpretation of protein–ligand interactions. The method does not solely suggest whether a compound may bind but it also provides structural hypotheses about its binding mode, including interacting residues, hydrogen bond formation, hydrophobic pocket occupation, and electrostatic contributions to affinity [52,53]. For this reason, docking is widely used to explain why a given antibacterial candidate appears promising, to predict which side-chain modifications on a common scaffold may strengthen binding, and to support a more rational interpretation

of structure–activity relationships [51,54]. Because scoring functions provide approximate estimates of relative binding tendency, compounds are typically ranked on this basis and advanced to experimental evaluation accordingly [51,53,54].

However, molecular docking is not a method of absolute predictive certainty. Limited representation of protein flexibility, approximate treatment of water molecules and solvent effects, and the inability of

scoring functions to accurately capture true binding free energy may all generate false-positive and false-negative results [52,55,56]. Docking should therefore be regarded primarily as a tool for candidate prioritization and hypothesis generation. Unless supported by additional approaches such as MIC testing, enzyme inhibition assay and mutation analysis, docking should not be relied on as direct evidence of antibacterial activity [53,55,56].

4.2 Practical Demonstration of Molecular Docking:

To demonstrate the application of computational approaches in antibiotic research, molecular docking of ciprofloxacin with *Escherichia coli* DNA gyrase B was performed using SwissDock. The protein structure (PDB ID: 4WUD) was obtained from the RCSB Protein Data Bank, while the ligand structure of ciprofloxacin (PubChem CID: 2764) was obtained from PubChem and prepared using its canonical SMILES representation. DNA gyrase B was selected because DNA gyrase is one of the principal bacterial targets of fluoroquinolone antibiotics and plays an essential role in DNA replication. Although fluoroquinolones primarily stabilize the DNA gyrase-DNA cleavage complex, the isolated GyrB structure provides a suitable model for demonstrating the principles of molecular docking and protein-ligand interaction analysis. After the ligand and target were prepared in SwissDock, docking was performed using the Attracting Cavities (AC) docking method. A defined search space centered at (9, 38, −14) with dimensions of 80 × 80 × 60 Å was used. Docking calculations were carried out with medium sampling exhaustivity, one region of interest (RIC = 1), and buried cavity prioritization. The resulting docking poses were subsequently visualized and analyzed using PyMOL.



Figure 1. DNA gyrase B structure obtained from the RCSB Protein Data Bank (PDB ID: 4WUD).



Figure 2. Defined search space used during docking analysis in SwissDock.



Cluster number	Cluster member	AC Score	SwissParam Score
0	1	246.730874	-7.3016
1	1	248.258539	-6.3595
2	1	248.754537	-7.3860
3	1	249.002283	-7.1045
4	1	249.634919	-6.6032
5	1	250.015347	-6.7395
6	1	250.036250	-6.8382
7	1	250.283773	-7.2954
8	1	250.330839	-6.3065
9	1	250.448600	-6.6156

Figure 3. SwissDock results showing docking clusters and predicted binding scores for ciprofloxacin.



Figure 4. PyMOL visualization of ciprofloxacin interacting with residues inside the predicted binding pocket of DNA gyrase B.



Figure 5. Interaction distances between ciprofloxacin and nearby amino acid residues visualized in PyMOL.

4.3 Docking Analysis:

Docking analysis predicted a favorable interaction between ciprofloxacin and DNA gyrase B. The highest-ranked docking pose produced an estimated binding free energy (ΔG) of approximately −7.30 kcal/mol. Visualization in PyMOL showed ciprofloxacin positioned within the predicted binding pocket, with several interaction distances of approximately 2–3 Å between the ligand and nearby amino acid residues. These observations demonstrate how molecular docking can generate structural hypotheses regarding protein-ligand interactions and assist in the early stages of antibacterial drug discovery. However, these results should be interpreted as preliminary computational predictions rather than direct evidence of antibacterial activity. Experimental validation is still required to confirm the biological relevance of the predicted interaction.

5: CONCLUSION

Antibiotic resistance is the major mechanistic basis for antibiotic treatment failure. Enzymatic inactivation chemically degrades the antibiotic, target modification disrupts binding, efflux systems reduce intracellular antibiotic concentration, and reduced permeability restricts access to the target site. In

clinical practice, these mechanisms usually reinforce one another and generate resistance phenotypes that are more robust [43–50]. Consequently, strategies for new antibiotic discovery must extend beyond the simple search for new targets and must incorporate the bacterial routes by which drugs are degraded, excluded, or functionally neutralized [43,44].

In this context, molecular docking is an important computational tool for prioritizing new antibacterial candidates, understanding target interactions, and rationalizing structure–activity relationships. Its main strength, however, emerges only when it is integrated with experimental validation, because biological activity, cell penetration, efflux susceptibility, and resistance to enzymatic degradation cannot be inferred from docking scores alone [51–56]. Overall, combining knowledge about antibiotic targets, resistance mechanisms, and structure-based computational methods is a very promising approach. It can help researchers better explain current treatment failures and develop stronger antibacterial drugs [43–56].

REFERENCES

1. Hutchings MI, Truman AW, Wilkinson B. Antibiotics: past, present and future. Curr Opin Microbiol. 2019;51:72-80. doi:10.1016/j.mib.2019.10.008

2. Aminov RI. A brief history of the antibiotic era: lessons learned and challenges for the future. Front Microbiol. 2010;1:134. doi:10.3389/fmicb.2010.00134

3. Waksman SA. What is an antibiotic or an antibiotic substance? Mycologia. 1947;39(5):565-569. doi:10.2307/3755196

4. Fleming A. On the antibacterial action of cultures of a Penicillium, with special reference to their use in the isolation of B. influenzae. Br J Exp Pathol. 1929;10(3):226-236.

5. Tan SY, Tatsumura Y. Alexander Fleming (1881-1955): discoverer of penicillin. Singapore Med J. 2015;56(7):366-367. doi:10.11622/smedj.2015105

6. Walsh C. Molecular mechanisms that confer antibacterial drug resistance. Nature. 2000;406(6797):775-781. doi:10.1038/35021219

7. Kohanski MA, Dwyer DJ, Collins JJ. How antibiotics kill bacteria: from targets to networks. Nat Rev Microbiol. 2010;8(6):423-435. doi:10.1038/nrmicro2333

8. Vollmer W, Blanot D, de Pedro MA. Peptidoglycan structure and architecture. FEMS Microbiol Rev. 2008;32(2):149-167. doi:10.1111/j.1574-6976.2007.00094.x

9. Lambert PA. Cellular impermeability and uptake of biocides and antibiotics in Gram-positive bacteria and mycobacteria. J Appl Microbiol. 2002;92:46S-54S. doi:10.1046/j.1365-2672.92.5s1.7.x

10. World Health Organization. Antimicrobial resistance. Geneva: WHO; 2023. Available from: https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance

11. Murray CJL, Ikuta KS, Sharara F, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629-655. doi:10.1016/S0140-6736(21)02724-0

12. Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. PT. 2015;40(4):277-283.

13. O'Neill J. Tackling Drug-Resistant Infections Globally: Final Report and Recommendations. London: Review on Antimicrobial Resistance; 2016.

14. Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2019. Atlanta: CDC; 2019. Available from: https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf

15. Dadgostar P. Antimicrobial resistance: implications and costs. Infect Drug Resist. 2019;12:3903-3910. doi:10.2147/IDR.S234610

16. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov. 2007;6(1):29-40. doi:10.1038/nrd2201

17. Barh D, Tiwari S, Jain N, et al. Computational biology and bioinformatics approaches for infectious diseases. Interdiscip Sci. 2011;3(1):1-7. doi:10.1007/s12539-011-0070-8

18. Chandra N, Padiadpu J. Systems biology for infectious diseases. Brief Funct Genomics. 2013;12(5):381-389. doi:10.1093/bfgp/elt021

19. Sarkar IN, Sobie EA. Quantitative systems pharmacology and computational medicine. Brief Bioinform. 2015;16(6):1017-1026. doi:10.1093/bib/bbv075

20. Tipper DJ, Strominger JL. Mechanism of action of penicillins: a proposal based on their structural similarity to acyl-D-alanyl-D-alanine. Proc Natl Acad Sci U S A. 1965;54(4):1133-1141. doi:10.1073/pnas.54.4.1133

21. Sauvage E, Kerff F, Terrak M, Ayala JA, Charlier P. The penicillin-binding proteins: structure and role in peptidoglycan biosynthesis. FEMS Microbiol Rev. 2008;32(2):234-258. doi:10.1111/j.1574-6976.2008.00105.x

22. Typas A, Banzhaf M, Gross CA, Vollmer W. From the regulation of peptidoglycan synthesis to bacterial growth and morphology. Nat Rev Microbiol. 2012;10(2):123-136. doi:10.1038/nrmicro2677

23. Tomasz A. The mechanism of the irreversible antimicrobial effects of penicillins: how the beta-lactam antibiotics kill and lyse bacteria. Annu Rev Microbiol. 1979;33:113-137. doi:10.1146/annurev.mi.33.100179.000553

24. Kitano K, Tomasz A. Triggering of autolytic cell wall degradation in Escherichia coli by beta-lactam antibiotics. Antimicrob Agents Chemother. 1979;16(6):838-848. doi:10.1128/AAC.16.6.838

25. Cho H, Uehara T, Bernhardt TG. Beta-lactam antibiotics induce a lethal malfunctioning of the bacterial cell wall synthesis machinery. Cell. 2014;159(6):1300-1311. doi:10.1016/j.cell.2014.11.017

26. Wilson DN. Ribosome-targeting antibiotics and mechanisms of bacterial resistance. Nat Rev Microbiol. 2014;12(1):35-48. doi:10.1038/nrmicro3155

27. Lin J, Zhou D, Steitz TA, Polikanov YS, Gagnon MG. Ribosome-targeting antibiotics: modes of action, mechanisms of resistance, and implications for drug design. Annu Rev Biochem. 2018;87:451-478. doi:10.1146/annurev-biochem-062917-011942

28. Brodersen DE, Clemons WM Jr, Carter AP, Morgan-Warren RJ, Wimberly BT, Ramakrishnan V. The structural basis for the action of the antibiotics tetracycline, pactamycin, and hygromycin B on the 30S ribosomal subunit. Cell. 2000;103(7):1143-1154. doi:10.1016/S0092-8674(00)00216-6

29. Hansen JL, Ippolito JA, Ban N, Nissen P, Moore PB, Steitz TA. The structures of four macrolide antibiotics bound to the large ribosomal subunit. Mol Cell. 2002;10(1):117-128. doi:10.1016/S1097-2765(02)00570-1

30. Demirci H, Murphy F IV, Murphy E, Gregory ST, Dahlberg AE, Jogl G. A structural basis for streptomycin-induced misreading of the genetic code. Nat Commun. 2013;4:1355. doi:10.1038/ncomms2346

31. Drlica K, Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev. 1997;61(3):377-392. doi:10.1128/MMBR.61.3.377-392.1997

32. Hooper DC, Jacoby GA. Topoisomerase inhibitors: fluoroquinolone mechanisms of action and resistance. Cold Spring Harb Perspect Med. 2016;6(9):a025320. doi:10.1101/cshperspect.a025320

33. Campbell EA, Korzheva N, Mustaev A, Murakami K, Nair S, Goldfarb A, Darst SA. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell. 2001;104(6):901-912. doi:10.1016/S0092-8674(01)00286-0

34. Mosaei H, Zenkin N. Inhibition of RNA polymerase by rifampicin and rifamycin-like molecules. EcoSal Plus. 2020;9(1):ESP-0017-2019. doi:10.1128/ecosalplus.ESP-0017-2019

35. Poirel L, Jayol A, Nordmann P. Polymyxins: antibacterial activity, susceptibility testing, and resistance mechanisms encoded by plasmids or chromosomes. Clin Microbiol Rev. 2017;30(2):557-596. doi:10.1128/CMR.00064-16

36. Moubareck CA. Polymyxins and bacterial membranes: a review of antibacterial activity and mechanisms of resistance. Membranes (Basel). 2020;10(8):181. doi:10.3390/membranes10080181

37. Nation RL, Li J, Cars O, Couet W, Dudley MN, Kaye KS, et al. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. Lancet Infect Dis. 2015;15(2):225-234. doi:10.1016/S1473-3099(14)70850-3

38. Zavascki AP, Nation RL. Nephrotoxicity of polymyxins: is there any difference between colistimethate and polymyxin B? Antimicrob Agents Chemother. 2017;61(3):e02319-16. doi:10.1128/AAC.02319-16

39. Bourne CR. Utility of the biosynthetic folate pathway for targets in antimicrobial discovery. Antibiotics (Basel). 2014;3(1):1-28. doi:10.3390/antibiotics3010001

40. Fernández-Villa D, Aguilar MR, Rojo L. Folic acid antagonists: antimicrobial and immunomodulating mechanisms and applications. Int J Mol Sci. 2019;20(20):4996. doi:10.3390/ijms20204996

41. Achari A, Somers DO, Champness JN, Bryant PK, Rosemond J, Stammers DK. Crystal structure of the anti-bacterial sulfonamide drug target dihydropteroate synthase. Nat Struct Biol. 1997;4(6):490-497. doi:10.1038/nsb0697-490

42. Bushby SRM, Hitchings GH. Trimethoprim, a sulphonamide potentiator. Br J Pharmacol Chemother. 1968;33(1):72-90. doi:10.1111/j.1476-5381.1968.tb00475.x

43. Blair JMA, Webber MA, Baylay AJ, Ogbolu DO, Piddock LJV. Molecular mechanisms of antibiotic resistance. Nat Rev Microbiol. 2015;13(1):42-51. doi:10.1038/nrmicro3380

44. Darby EM, Trampari E, Siasat P, Gaya MS, Alav I, Webber MA, Blair JMA. Molecular mechanisms of antibiotic resistance revisited. Nat Rev Microbiol. 2023;21(5):280-295. doi:10.1038/s41579-022-00820-y

45. Bush K. Past and Present Perspectives on β-Lactamases. Antimicrob Agents Chemother. 2018;62(10):e01076-18. doi:10.1128/AAC.01076-18

46. Philippon A, Arlet G, Jacoby GA. Plasmid-determined AmpC-type beta-lactamases. Antimicrob Agents Chemother. 2002;46(1):1-11. doi:10.1128/AAC.46.1.1-11.2002

47. Li XZ, Plésiat P, Nikaido H. The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria. Clin Microbiol Rev. 2015;28(2):337-418. doi:10.1128/CMR.00117-14

48. Piddock LJV. Multidrug-resistance efflux pumps—not just for resistance. Nat Rev Microbiol. 2006;4(8):629-636. doi:10.1038/nrmicro1464

49. Nikaido H. Molecular basis of bacterial outer membrane permeability revisited. Microbiol Mol Biol Rev. 2003;67(4):593-656. doi:10.1128/MMBR.67.4.593-656.2003

50. Delcour AH. Outer membrane permeability and antibiotic resistance. Biochim Biophys Acta. 2009;1794(5):808-816. doi:10.1016/j.bbapap.2008.11.005

51. Kitchen DB, Decornez H, Furr JR, Bajorath J. Docking and scoring in virtual screening for drug discovery: methods and applications. Nat Rev Drug Discov. 2004;3(11):935-949. doi:10.1038/nrd1549

52. Paggi JM, Pandit A, Dror RO. The art and science of molecular docking. Annu Rev Biochem. 2024;93:389-410. doi:10.1146/annurev-biochem-030123-114700

53. Torres PHM, Sodero ACR, Jofily P, Silva-Jr FP. Key topics in molecular docking for drug design. Int J Mol Sci. 2019;20(18):4574. doi:10.3390/ijms20184574

54. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem. 2004;47(7):1739-1749. doi:10.1021/jm0306430

55. Huang N, Shoichet BK, Irwin JJ. Benchmarking sets for molecular docking. J Med Chem. 2006;49(23):6789-6801. doi:10.1021/jm0608356

56. Ramírez D, Caballero J. Is it reliable to take the molecular docking top scoring position as the best solution without considering available structural data? Molecules. 2018;23(5):1038. doi:10.3390/molecules23051038